双次自体造血干细胞移植治疗恶性血液病的临床分析  

Double Autologous Hematopoietic Stem Cell Transplantation in Hematological Malignancies

作　　者：郑冬[1] 张国材[1] 谭恩勋[1] 洪文德[1] 罗绍凯[1] 彭爱华[1] 李娟[1] 童秀珍[1] 赖凤珍[1] 

机构地区：[1]中山医科大学附属第一医院血液内科,广东广州510080

出　　处：《癌症》2001年第6期644-646,共3页Chinese Journal of Cancer

摘　　要：目的：探讨双次自体造血干细胞移植对恶性血液病的临床疗效。方法：回顾性分析我院 １９９５年～１９９９年间１２例双次自体造血干细胞移植的资料，并与同期１７例单次自体移植效果比较。结果：双次移植１２例患者移植后持续缓解６～６８个月，中位数２７个月，其中８例（６６．７％）至今无病生存，１例于第二次移植后６个月出现复发，３例死于移植相关性疾病。单次自体移植１７例患者移植后持续缓解１～３６个月，中位数１２个月，其中６例（３．３％）至今无病生存，８例肿瘤复发，３例死于移植相关性疾病。结论：双次自体造血干细胞移植治疗恶性血液病的疗效较好，其移植后１８个月生存率有优于单次自体造血于细胞移植的趋势。Objective: This study was designed to investigate the outcome of double autologous hematopoietic stem cell transplantation (Double - AHSCT ) in hematological malignancies. Methods: The clinical data of 12 patients who underwent Double-AHSCT between January 1995 and January 1999 were analyzed retrospectively and the outcome were compared with that of 17 patients who received single autologous hematopoietic stem cell transplantation (Single-AHSCT) in the same period. Results: The duration of continuous remission in 12 patients undergoing Double-AHSCT ranged from 6 to 68 months (mean 27 months). Among them, eight patients (66. 7% ) were still alive without relapse up to now. While one patient had relapsed 6 months after second grafting. Three patients died from diseases related to graft. The patients who received Single-AHSCT had a continuous remission of 1 - 36 months after graft (mean 12 months). Six of the 17 patients were still alive in good condition. Eight patients relapsed and 3 patients died from diseases related to graft. Conclusion: Good outcome were showed in Double-AHSCT for the treatment of hematological malignancies. The 18-month survival rate in Double-AHSCT tended to be better than that in Single-AHSCT.

关 键 词：造血干细胞移植 血液肿瘤 临床分析 AHSCT 术后并发症 

分 类 号：R730.5[医药卫生—肿瘤]